EMA Domperidone Guide Could Hurt Xian Janssen Sales In China
This article was originally published in PharmAsia News
Executive Summary
The guide suggested by the European Medicine Agency limiting domperidone, marketed under Motilium by Johnson & Johnson to treat nausea and vomiting would cause sale losses of up to 80% in China where it is more widely used for stomach diseases, says an OTC commercial expert.